Literature DB >> 22743836

[Gastrointestinal dysfunction in idiopathic Parkinson's disease].

K Del Tredici1, W H Jost.   

Abstract

Gastrointestinal dysfunction is frequent during all stages of Parkinson's disease. The entire gastrointestinal tract becomes involved and symptoms include sialorrhea, dysphagia (difficulties swallowing), delayed gastric emptying, absorption problems and constipation. These non-motor symptoms can be manifested even prior to the initial Parkinson diagnosis, i.e. during the so-called premotor phase of the disorder and may serve as prodromal markers of the early non-motor disease phase. In addition to causing patients major discomfort and a reduced quality of life, such gastrointestinal complaints can also negatively influence the therapy with antiparkinsonian medications. Thus, delayed gastric emptying is an important cause of unforeseen motor fluctuations.Gastrointestinal dysfunction is attributable in part to the presence of synucleinopathy (Lewy pathology) both in the dorsal motor nucleus of the vagus nerve, which supplies the parasympathetic innervation of the gut from the distal esophagus to the left colonic flexure, as well as in the intramural Meissner and Auerbach plexuses of the enteric nervous system (ENS). In all probability the development of the lesions in the lower brainstem and in the ENS precedes neurodegeneration of the dopaminergic nigrostriatal system. From a diagnostic standpoint, neurologists need not only a carefully taken patient history and the clinical findings but also esophagography (barium study), gastric scintigraphy and assessment of the colonic transit time. The therapeutic options for impaired upper gastrointestinal tract motility are still limited. Sialorrhea can be reduced by prescribing anticholinergics or injections of botulinum toxin and the peristalsis can be modulated by domperidone. In the lower gastrointestinal tract, constipation can be conservatively treated by using macrogol (polyethylene glycol) and, in the future, perhaps by serotonine (5-HT4) agonists.

Entities:  

Mesh:

Year:  2012        PMID: 22743836     DOI: 10.1007/s00115-012-3575-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  104 in total

1.  Autonomic dysfunction in men with Parkinson's disease.

Authors:  C Singer; W J Weiner; J R Sanchez-Ramos
Journal:  Eur Neurol       Date:  1992       Impact factor: 1.710

2.  Gastric emptying time and gastric motility in patients with Parkinson's disease.

Authors:  R Hardoff; M Sula; A Tamir; A Soil; A Front; S Badarna; S Honigman; N Giladi
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

3.  Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons.

Authors:  Heiko Braak; Magdalena Sastre; Jürgen R E Bohl; Rob A I de Vos; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2007-02-09       Impact factor: 17.088

Review 4.  Gastrointestinal dysfunction in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

5.  Serum noradrenaline response to standing up in patients with Parkinson's disease.

Authors:  J T Turkka; K K Juujärvi; T O Lapinlampi; V V Myllylä
Journal:  Eur Neurol       Date:  1986       Impact factor: 1.710

6.  Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.

Authors:  Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Riboldazzi; Daniela Calandrella; Gabriele Brunetti; Claudio Pacchetti
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

7.  Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.

Authors:  Alberto Albanese; Giuseppe Brisinda; Anna Rita Bentivoglio; Giorgio Maria
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

8.  Measurement of blood pressure and heart-rate variation while resting supine and standing for the evaluation of autonomic dysfunction.

Authors:  Y Kuroiwa; T Wada; H Tohgi
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

9.  Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.

Authors:  Christopher B Forsyth; Kathleen M Shannon; Jeffrey H Kordower; Robin M Voigt; Maliha Shaikh; Jean A Jaglin; Jacob D Estes; Hemraj B Dodiya; Ali Keshavarzian
Journal:  PLoS One       Date:  2011-12-01       Impact factor: 3.240

10.  Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.

Authors:  Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more
  5 in total

Review 1.  Hypersalivation: update of the German S2k guideline (AWMF) in short form.

Authors:  Armin Steffen; Wolfgang Jost; Tobias Bäumer; Dirk Beutner; Sabine Degenkolb-Weyers; Martin Groß; Maria Grosheva; Samer Hakim; Kai G Kahl; Rainer Laskawi; Rebekka Lencer; Jan Löhler; Thekla Meyners; Saskia Rohrbach-Volland; Rainer Schönweiler; Sara-Christina Schröder; Sebastian Schröder; Heidrun Schröter-Morasch; Maria Schuster; Susanne Steinlechner; Roland Urban; Orlando Guntinas-Lichius
Journal:  J Neural Transm (Vienna)       Date:  2019-04-10       Impact factor: 3.575

Review 2.  Na+ leak-current channel (NALCN) at the junction of motor and neuropsychiatric symptoms in Parkinson's disease.

Authors:  Merve Kasap; Donard S Dwyer
Journal:  J Neural Transm (Vienna)       Date:  2021-05-07       Impact factor: 3.575

3.  Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson's Disease: A Pilot Study.

Authors:  Jayme D Mancini; Sheldon Yao; Luis R Martinez; Haque Shakil; To Shan Li
Journal:  Neurology (ECronicon)       Date:  2021-01-30

4.  Dietary fat and antioxidant vitamin intake in patients of neurodegenerative disease in a rural region of Jalisco, Mexico.

Authors:  Mónica Navarro-Meza; Genaro Gabriel-Ortiz; Fermín P Pacheco-Moisés; José A Cruz-Ramos; Antonio López-Espinoza
Journal:  Nutr Neurosci       Date:  2013-11-20       Impact factor: 4.994

Review 5.  Parkinson's disease between internal medicine and neurology.

Authors:  Ilona Csoti; Wolfgang H Jost; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.